56921
Strep B ChromoSelect Selektiv-Agar-Basis
suitable for microbiology, NutriSelect® Plus
Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)
About This Item
UNSPSC-Code:
41171606
NACRES:
NA.85
Empfohlene Produkte
Sterilität
non-sterile
Qualitätsniveau
Form
powder
Haltbarkeit
limited shelf life, expiry date on the label
Zusammensetzung
agar, 15.0 g/L
buffers, 2.5 g/L
chromogenic mixture, 2.54 g/L
protein hydrolysate, 17.5 g/L
selective agents, 0.110 g/L
Hersteller/Markenname
NutriSelect® Plus
pH-Endwert
7.3±0.2 (25 °C)
Anwendung(en)
clinical testing
veterinary
microbiology
Lagertemp.
2-8°C
Eignung
Streptococcus spp.
Anwendung
Strep B ChromoSelect Selective Agar Base is recommended for selective isolation of Group B streptococci.
Angaben zur Herstellung
Suspend 37.65 grams in 1000 ml distilled water. Heat to boiling to dissolve the medium completely. DO NOT AUTOCLAVE. Cool to 45-50°C and aseptically add the rehydrated contents of one vial of Strep B ChromoSelect Selective Supplement (Cat. No. 92650). Mix well and pour in sterile Petri plates.
Fußnote
We offer two media types: the superior granulated GranuCult® and the cost-efficient powdered NutriSelect® culture media, depending on your needs.
The designations basic, plus, or prime are added to indicate the quality control level, from basic quality control to standard QC plus to prime for full regulatory compliance.
The designations basic, plus, or prime are added to indicate the quality control level, from basic quality control to standard QC plus to prime for full regulatory compliance.
Rechtliche Hinweise
GRANUCULT is a registered trademark of Merck KGaA, Darmstadt, Germany
NutriSelect is a registered trademark of Merck KGaA, Darmstadt, Germany
Lagerklassenschlüssel
13 - Non Combustible Solids
WGK
WGK 2
Flammpunkt (°F)
Not applicable
Flammpunkt (°C)
Not applicable
Choose from one of the most recent versions:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports, 45(RR-7), 1-24 (1996-05-31)
Group B streptococcus is a leading cause of serious neonatal infection. Most neonatal GBS infections can be prevented through the use of intrapartum antimicrobial prophylaxis in women who are at increased risk for transmitting the infection to their newborns. However
B F Anthony et al.
The Journal of infectious diseases, 137(5), 524-530 (1978-05-01)
A longitudinal, three-year study of the epidemiology of group B Streptococcus was conducted with repeated (four to 11) observations of 382 patients followed through pregnancy, delivery, and the postpartum period. Group B streptococci (2.3% of which were nonhemolytic) were isolated
Murray, P.R., E.J. Baron, J.H. Jorgensen, M.A. Pfaller, and R. H. Yolken (Eds.)
Manual of Clinical Microbiology (2003)
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung.